source
- Agios’ second shot at sickle cell disease falls shortAgios said it is dropping a next-generation sickle cell disease drug after lackluster results from a mid-stage trial. The drug, known as tebapivat, represented Agios’ second shot at the disease, an…Endpoints · 8d ago↗ source
- Notes from a peptide meetupWith an FDA advisory committee set to decide this week whether it recommends that several popular peptides be reclassified, I wanted to learn more. Cue a last-minute ticket purchase to ...Endpoints · 8d ago↗ source
- Agios axes next-gen sickle cell candidate after it fails to best Novo’s assetAgios Pharmaceuticals’ sickle cell disease candidate didn’t prove any better than Novo Nordisk’s investigational PK activator or the biopharma’s own asset that is currently under FDA review for the…BioSpace